Multicentre, International Neoadjuvant Randomized Double-blind Trial Comparing Fulvestrant to a Combination of Fulvestrant and Palbociclib (CDK 4/6 Inhibitor) in Patients With Operable Luminal Breast Cancer Responding to Fulvestrant

Trial Profile

Multicentre, International Neoadjuvant Randomized Double-blind Trial Comparing Fulvestrant to a Combination of Fulvestrant and Palbociclib (CDK 4/6 Inhibitor) in Patients With Operable Luminal Breast Cancer Responding to Fulvestrant

Recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Feb 2018

At a glance

  • Drugs Fulvestrant (Primary) ; Goserelin (Primary) ; Palbociclib (Primary)
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms SAFIA
  • Most Recent Events

    • 28 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top